Search research articles
Contact Us
Filters
Showing results (11-20 of 65) with videos related to
Page
of 7
Sort By:
Surgical Oncology Clinics of North America
|
September 10, 2013
Advances in molecular and clinical subtyping of breast cancer and their implications for therapy
Karen A Cadoo, Tiffany A Traina, Tari A King
Women'S Health (London, England)
|
December 17, 2009
Bevacizumab for advanced breast cancer
Shari B Goldfarb, Tiffany A Traina, Maura N Dickler
Gynecologic Oncology
|
September 24, 2004
Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature
Tiffany A Traina, Paul Sabbatini, Carol Aghajanian, et al.
Targeted Oncology
|
October 31, 2009
Targeting insulin-like growth factor type 1 receptor in cancer therapy
Francesco Atzori, Tiffany A Traina, Maria Teresa Ionta, et al.
AIDS Patient Care and Stds
|
May 21, 2014
Tolerability of chemotherapy in HIV-infected women with breast cancer: are there prognostic implications?
Lalitha Parameswaran, Ying Taur, Monika K Shah, et al.
The Oncologist
|
July 23, 2025
Datopotamab Deruxtecan-Associated Select Adverse Events: Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management
Aaron Lisberg, Laura A Huppert, Balazs Halmos, et al.
Endocrine-Related Cancer
|
February 28, 2015
Targeting the androgen receptor in prostate and breast cancer: several new agents in development
Tracy Proverbs-Singh, Jarett L Feldman, Michael J Morris, et al.
JCO Oncology Practice
|
January 7, 2026
Real-World Treatment Patterns and Outcomes for Patients With Metastatic Triple-Negative Breast Cancer in the United States: An Observational Study
Simon M Collin, Sam Hillman, Chintal H Shah, et al.
Breast Disease
|
June 4, 2010
Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling
Tiffany A Traina, Ute Dugan, Brian Higgins, et al.
NPJ Breast Cancer
|
January 19, 2024
Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer
Kelly E McCann, Shari B Goldfarb, Tiffany A Traina, et al.
Page
of 7
Search research articles
Search
Showing results (11-20 of 65) with videos related to
Sort By:
Page
of 7
Surgical Oncology Clinics of North America
|
September 10, 2013
Advances in molecular and clinical subtyping of breast cancer and their implications for therapy
Karen A Cadoo, Tiffany A Traina, Tari A King
Women'S Health (London, England)
|
December 17, 2009
Bevacizumab for advanced breast cancer
Shari B Goldfarb, Tiffany A Traina, Maura N Dickler
Gynecologic Oncology
|
September 24, 2004
Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature
Tiffany A Traina, Paul Sabbatini, Carol Aghajanian, et al.
Targeted Oncology
|
October 31, 2009
Targeting insulin-like growth factor type 1 receptor in cancer therapy
Francesco Atzori, Tiffany A Traina, Maria Teresa Ionta, et al.
AIDS Patient Care and Stds
|
May 21, 2014
Tolerability of chemotherapy in HIV-infected women with breast cancer: are there prognostic implications?
Lalitha Parameswaran, Ying Taur, Monika K Shah, et al.
The Oncologist
|
July 23, 2025
Datopotamab Deruxtecan-Associated Select Adverse Events: Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management
Aaron Lisberg, Laura A Huppert, Balazs Halmos, et al.
Endocrine-Related Cancer
|
February 28, 2015
Targeting the androgen receptor in prostate and breast cancer: several new agents in development
Tracy Proverbs-Singh, Jarett L Feldman, Michael J Morris, et al.
JCO Oncology Practice
|
January 7, 2026
Real-World Treatment Patterns and Outcomes for Patients With Metastatic Triple-Negative Breast Cancer in the United States: An Observational Study
Simon M Collin, Sam Hillman, Chintal H Shah, et al.
Breast Disease
|
June 4, 2010
Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling
Tiffany A Traina, Ute Dugan, Brian Higgins, et al.
NPJ Breast Cancer
|
January 19, 2024
Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer
Kelly E McCann, Shari B Goldfarb, Tiffany A Traina, et al.
Page
of 7